PAS
ASND icon

Point72 Asia (Singapore)’s Ascendis Pharma A/S ASND Stock Holding History

Point72 Asia (Singapore)’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-202
Closed -$27.9K – 868
2024
Q4 		$27.9K Buy
+202
New +$26.6K 0.01% 618

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asia (Singapore)'s ASND Position: Q1 2025 in Review

Point72 Asia (Singapore) sold out of Ascendis Pharma A/S (ASND) in Q1 2025, closing a stake of 202 shares — an estimated $27.9K sold.

Point72 Asia (Singapore) first reported a position in ASND in Q4 2024 and held it in 1 quarter. The position peaked at $27.9K in Q4 2024. 244 funds tracked by Wall St. Rank hold ASND as of Q1 2025.

  • Point72 Asia (Singapore) reported no remaining Ascendis Pharma A/S position as of Q1 2025 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 202 Ascendis Pharma A/S shares in Q1 2025, an estimated $27.9K.
  • Point72 Asia (Singapore) first reported a position in Ascendis Pharma A/S in Q4 2024 and held it in 1 quarter.
  • Point72 Asia (Singapore)'s Ascendis Pharma A/S position peaked at $27.9K in Q4 2024.
  • 244 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2025.

Based on Point72 Asia (Singapore)'s 13F filing for Q1 2025, filed 15 May 2025.